New Avenues for Optimal Treatment of Atrial Fibrillation and Stroke Prevention.

De Marchis, Gian Marco; Sposato, Luciano A; Kühne, Michael; Dittrich, Tolga D; Bonati, Leo H; Fischer, Urs; Chaturvedi, Seemant (2021). New Avenues for Optimal Treatment of Atrial Fibrillation and Stroke Prevention. Stroke, 52(4), pp. 1490-1499. American Heart Association 10.1161/STROKEAHA.120.032060

Text De_Marchis__2021__New_Avenues_for_Optimal_Treatment.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (596kB) | Request a copy

One in 3 individuals free of atrial fibrillation (AF) at index age 55 years is estimated to develop AF later in life. AF increases not only the risk of ischemic stroke but also of dementia, even in stroke-free patients. In this review, we address recent advances in the heart-brain interaction with focus on AF. Issues discussed are (1) the timing of direct oral anticoagulants start following an ischemic stroke; (2) the comparison of direct oral anticoagulants versus vitamin K antagonists in early secondary stroke prevention; (3) harms of bridging with heparin before direct oral anticoagulants; (4) importance of appropriate direct oral anticoagulants dosing; (5) screening for AF in high-risk populations, including the role of wearables; (6) left atrial appendage occlusion as an alternative to oral anticoagulation; (7) the role of early rhythm-control therapy; (8) effect of lifestyle interventions on AF; (9) AF as a risk factor for dementia. An interdisciplinary approach seems appropriate to address the complex challenges posed by AF.

Interest & Impact

Downloads

1 since deposited on 13 Jul 2021
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item